Hikma and GSK agree to cease potential acquisition discussions in Egypt and Tunisia

London, 11 March 2021 – On 26 January 2021, Hikma Pharmaceuticals PLC (Hikma) announced that it had entered into a non-binding term sheet with GlaxoSmithKline PLC (GSK) for the purposes of potentially acquiring GSK’s pharmaceutical and consumer businesses in Egypt and its pharmaceutical business in Tunisia (the Proposed Transaction).

Press Release Corporate 11 March 2021


Hikma today confirms that both companies have agreed to cease discussions regarding the Proposed Transaction and, accordingly, Hikma will not be launching a Mandatory Tender Offer process to acquire the shares in GlaxoSmithKline SAE Egypt.

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.